Hansoh Pharmaceutical Group Company Limited

B7-H3 ADC Ris-Rez Cuts Death Risk 54% in Relapsed Small-Cell Lung Cancer

- The Phase III ARTEMIS-008 trial showed risvutatug rezetecan reduced the risk of death by 54% versus topotecan in relapsed small-cell lung cancer. - Median overall survival reached 18.5 months with Ris-Rez versus 10.3 months with topotecan after a median follow-up of 12.2 months. - Grade 3 or higher treatment-related adverse events occurred in 60.9% of Ris-Rez patients versus 78.2% with topotecan, mostly hematologic toxicities. - GSK, which holds ex-China rights to the B7-H3-directed antibody-drug conjugate, is advancing a global development program including the Phase III EMBOLD SCLC-301 trial.